Vascular access versus the effect of statins on inflammation and fibrinolysis in renal dialysis patients

• Tipo: Artigo em Revista Científica Internacional
• Data: 2013

Autores

Maria do Sameiro Faria (Autor) Outra; Sandra Ribeiro (Autor) Outra; Petronila Rocha Pereira (Autor) Outra; Vasco Miranda (Autor) Outra; Alexandre Quintanilha (Autor) Outra; Flavio Reis (Autor) Outra; Elisio Costa (Autor) FFUP; Luis Belo (Autor) FFUP; Alice Santos Silva (Autor) FFUP

Revista

Título: Journal of Vascular Access

Vol. 14

Páginas: 335-341

ISSN: 1129-7298

Editora: WICHTIG PUBLISHING

Indexação

ISI Web of Knowledge - 2 Citações

Scopus - 3 Citações

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina clínica

Outras Informações

ID Authenticus: P-008-J93

DOI: 10.5301/jva.5000132

Abstract (EN): Purpose: The aim of this work was to assess the effect of statin therapy on inflammatory and fibrinolytic/endothelial (dys) function markers in end-stage renal disease (ESRD) patients under hemodialysis (HD), according to the type of vascular access. Methods: This transversal study includes 191 ESRD patients under regular HD, divided into four groups according to vascular access and statin therapy: 87 patients with arteriovenous fistula (AVF) and no statins (AVF-NS), 61 with AVF and statins (AVF-S), 27 with central venous dialysis catheter (CVC) and no statins (CVC-NS) and 16 with CVC and statins (CVC-S). The basic lipid profile and fibrinolytic/endothelial cell function markers were assessed. Results: Patients with CVC presented significantly higher levels of D-dimers compared with AVF groups. CVC-NS patients also presented the highest IL-6 values, which were significantly higher than those presented by CVC-S patients. AVF-S patients presented significantly higher t-PA and PAI-1 values and lower adiponectin levels compared with AVF-NS. Conclusions: Our results demonstrate that patients with CVC, particularly those not under statin therapy, present a higher production and turnover of fibrin. We also found that statin therapy decreases inflammation in CVC patients but is associated with a reduction of adiponectin and increased endothelial function marker levels in AVF patients.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 7